Chemo, Immunotherapy, and Heated Belly Chemo for Stomach Cancer Spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests combining standard chemotherapy and immunotherapy (tirelizumab) with heated chemotherapy given directly into the belly. It aims to treat stomach cancer that has spread to the abdominal lining, and may help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stomach cancer that has spread to the lining of your belly (called the peritoneum), but the spread is not too extensive.
- You have not had chemotherapy, radiation, targeted therapy, or immunotherapy before.
- You do not have other cancers, active autoimmune diseases, or serious heart/lung conditions.
- Your organs (kidneys, liver, blood cells) are working well enough, as shown by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This Phase 2 trial studies a combination treatment for stomach (or stomach-to-esophagus) cancer that has spread to the belly lining. It tests whether adding the immunotherapy drug sintilimab to a procedure called HIPEC can improve outcomes for people who have not had prior treatment.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial tests a combination of immunotherapy and chemotherapy given before surgery to shrink stomach cancers that are particularly thick or large. It aims to see if this approach can make these hard-to-treat tumors easier to remove and improve outcomes.
This trial tests a combination of an immunotherapy drug (PD-1 antibody) plus chemotherapy or targeted therapy, followed by surgery, for people with stomach cancer that has spread to a limited number of other sites. The goal is to see if this approach can help shrink the cancer enough to make surgery more effective.
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.